Study Type–Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? In bladder‐sparing approach incorporating TURBT and …

Purpose: We evaluated trends in oncologic characteristics and outcomes as well as
perioperative management among patients undergoing radical cystectomy at Memorial …

Introduction Although radical cystectomy (RC) is the gold standard treatment for muscle
invasive bladder cancer it is associated with perioperative complications, readmissions, and …

Objective To compare rates of early morbidity after radical cystectomy in patients treated with
or without induction chemoradiotherapy (CRT) using a standardized reporting methodology …

Objective To study short-term (< 90 days) morbidity and mortality following radical
cystectomy (RC) for bladder cancer and identify modifiable risk factors associated with …

Context Neoadjuvant chemotherapy before radical cystectomy (RC) is the preferred initial
option for muscle-invasive bladder cancer (BCa). As in rectal and breast cancer, pathologic …

Importance Despite existing evidence of a benefit associated with cisplatin-based adjuvant
chemotherapy (AC) after radical cystectomy (RC) for chemotherapy-naive patients with …

Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to
improve overall survival in muscle invasive bladder cancer; however utilization rates remain …

Objectives To investigate delays to neoadjuvant chemotherapy (NAC) and radical
cystectomy (RC) and their effect on outcomes in a large national registry of patients with …

BACKGROUND: The optimal treatment strategy for muscle-invasive bladder cancer (BCa)
remains controversial. OBJECTIVE: Better define the long-term outcomes of radical …